For information on related topics, see our breast cancer summary page and our guideline on suspected cancer developing breast cancer take tamoxifen, over 10 years (the 5 years of taking tamoxifen plus a further 5 years afterwards): about 35 women (15 fewer) will develop breast cancer • about 965 women will not
Tamoxifen and raloxifene are the only drugs approved in the US to help lower the risk of breast cancer, although for some women, other drugs called aromatase inhibitors might
73 [ 27 ], we estimate it could cost approximately £9340 to
1 A collaborative meta-analysis
Currently, the only oestrogen receptor modulators tamoxifen and raloxifene are FDA-approved drugs for breast prevention in postmenopausal women with high risk
Corinne
Researchers with the
90% 10% will develop Most women will NEVER develop breast cancer For some women with breast cancer, taking adjuvant tamoxifen (Nolvadex®) for 10 years after primary treatment leads to a greater reduction in breast cancer recurrences and deaths than taking the drug for only 5 years, according to the results of a large international clinical trial
anastrozole – for women who have been through the menopause
You're considered at high risk if you score greater than 1
Some forms of hormone therapy for breast cancer work by blocking hormones from attaching to receptors on cancer cells
Talk to your doctor about increased risks for developing breast cancer and the treatments that are available
9% versus
Some men may continue taking it for longer than 5 years if the side effects are not causing problems
This may be when surgery is not appropriate or needs to be delayed
This is the largest reduction in risk seen in any of the four large breast cancer prevention trials that have been conducted to date
It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography)
We report the long-term follow-up of the IBIS-I trial, in which the participants and investigators remain largely masked to
It stops oestrogen from telling the cancer cells to grow
Treatment with raloxifene also lowers the risk of breast cancer in postmenopausal women